$19.42+0.67 (+3.57%)
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-11...
Key recent performance snapshot Aktis Oncology (AKTS) has drawn investor attention after a recent one-month return of about 40%, contrasting with a small decline over the past three months and a modest year-to-date loss. The clinical-stage company, focused on targeted radiopharmaceuticals for solid tumors, currently has a market value of about US$1.18 billion and last closed at US$21.26 per share. See our latest analysis for Aktis Oncology. For context, the recent 40% 1 month share price...
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Aktis Oncology, Inc. (NASDAQ:AKTS) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is […]
Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel “miniprotein” targeting approach, internally built supply chain capabilities, and two lead clinical pr
Aktis Oncology (NASDAQ:AKTS) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy to broaden the reach of targeted radiopharmaceutical therapy beyond today’s most established targets and to provide updates on its two lead clinical programs and manufacturing and